A landmark 21-year follow-up study has revealed that intensive lifestyle modifications are significantly more effective than the common medication metformin in preventing the development of multiple chronic diseases in adults with prediabetes. The research, which tracked participants from the historic Diabetes Prevention Program (DPP) and its subsequent Outcomes Study (DPPOS), provides a compelling case for the systemic benefits of diet and exercise over targeted pharmacological interventions. While metformin remains a gold standard for blood glucose management, this new analysis suggests that it lacks the broad-spectrum protective effects that a structured lifestyle program offers against the accumulation of various chronic conditions, a phenomenon known as multimorbidity.

Background and Context: The Growing Crisis of Prediabetes

Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be classified as type 2 diabetes. According to the Centers for Disease Control and Prevention (CDC), approximately 98 million American adults—more than one in three—have prediabetes. Without intervention, many of these individuals will progress to type 2 diabetes within five years. However, the medical community has increasingly recognized that the risks associated with prediabetes extend far beyond the eventual diagnosis of diabetes.

The Diabetes Prevention Program was launched in 1996 to determine whether lifestyle changes or metformin could delay or prevent the onset of type 2 diabetes. The original study was so successful that it was ended early in 2001 because the results were definitive: both lifestyle changes and metformin worked, but lifestyle changes were twice as effective. Since then, researchers have continued to monitor the original participants to understand the long-term implications of these interventions on aging and overall health.

Chronology of the 25-Year Research Effort

The journey of this data spans a quarter-century, beginning in the mid-1990s and concluding with the most recent analysis published in 2024.

1. 1996–1999 (Enrollment Phase): The DPP enrolled 3,234 adults at 27 clinical sites across the United States. These individuals were at high risk for type 2 diabetes due to elevated fasting glucose and impaired glucose tolerance.
2. 1996–2001 (The Randomized Trial): Participants were randomly assigned to one of three groups: an intensive lifestyle intervention (ILI) group, a metformin group (850 mg twice daily), or a placebo group.
3. 2002 (Initial Findings): The trial results were published, showing that ILI reduced the incidence of diabetes by 58% compared to the placebo, while metformin reduced it by 31%.
4. 2002–2021 (The Outcomes Study): Following the initial trial, the DPP Outcomes Study (DPPOS) was established to track the long-term health of the original cohort. This observational phase allowed researchers to see how early interventions affected the participants as they moved into old age.
5. 2021–2024 (Multimorbidity Analysis): Researchers focused on a subset of 1,173 participants who were enrolled in Medicare. This allowed for a detailed examination of insurance claims to track the development of various chronic conditions over two decades.

Deep Dive into the Study Findings

The primary objective of the latest analysis was to determine how many participants developed multimorbidity, defined as having two or more chronic conditions. These conditions included, but were not limited to, heart disease, kidney failure, cancer, arthritis, and pulmonary disease.

The data revealed a stark reality: aging with prediabetes almost inevitably leads to chronic illness. By the end of the follow-up period, 85% of all participants had developed at least two chronic conditions. On average, participants accumulated approximately five different diagnoses. However, the lifestyle group showed a distinct advantage.

In the intensive lifestyle intervention group, the rate of multimorbidity was 82%. In the metformin group, it was 85%, and in the placebo group, it was 87%. While the percentage differences seem small at first glance, the statistical analysis showed that the lifestyle group had a 21% lower risk of developing multimorbidity compared to the placebo group. Crucially, this benefit remained significant even after researchers removed diabetes from the list of conditions, indicating that the lifestyle changes were protecting the body in ways that had nothing to do with blood sugar levels.

Furthermore, when looking at the most "costly" pairs of conditions—combinations like heart failure and chronic kidney disease that place a massive burden on both the patient and the healthcare system—the lifestyle group fared significantly better. They were 43% less likely to develop these severe combinations than the placebo group. Metformin, despite its efficacy in glucose control, showed no significant difference from the placebo in preventing these complex disease clusters.

The Mechanics of Prevention: Why Lifestyle Outperforms Medication

The disparity between the results of the lifestyle group and the metformin group highlights a fundamental difference in how these interventions interact with human physiology.

Metformin is a targeted pharmaceutical. Its primary mechanism of action involves the liver, where it reduces the production of glucose, and the muscles, where it increases insulin sensitivity. While this is highly effective for managing the specific metabolic pathway of diabetes, its "reach" into other organ systems is limited.

In contrast, the intensive lifestyle program used in the DPP was a holistic intervention. It was built on three pillars:

• Weight Loss: A goal of losing at least 7% of initial body weight through caloric restriction and a low-fat diet.
• Physical Activity: A requirement of at least 150 minutes of moderate-intensity exercise, such as brisk walking, per week.
• Behavioral Support: Ongoing coaching, education, and social support to maintain these habits over time.

Exercise and weight loss trigger systemic biological changes. Physical activity improves cardiovascular health by strengthening the heart muscle and improving vascular elasticity. It reduces systemic inflammation—a root cause of many chronic diseases, including cancer and Alzheimer’s. Weight loss reduces the strain on joints (preventing arthritis) and improves lipid profiles (preventing atherosclerosis). Because lifestyle changes address the fundamental environment of the body’s cells, they provide a "multitargeted" defense that a single drug cannot match.

Implications for Public Health and Clinical Practice

The findings of this 21-year study have profound implications for how the medical community approaches prediabetes and aging. For decades, the conversation has centered on "preventing diabetes." This study suggests the goal should be broader: "preventing multi-system decline."

Medical experts and health economists suggest that these findings should lead to a shift in insurance coverage and physician recommendations. While prescribing a pill like metformin is easy and inexpensive in the short term, it does not provide the long-term "insurance" against multiple diseases that lifestyle support does. The structured support provided in the DPP—which included personal coaches and regular follow-ups—is rarely covered by standard insurance plans for prediabetic patients, despite its proven long-term efficacy.

The economic impact is also substantial. Multimorbidity is the primary driver of healthcare costs in the elderly. Patients with five or more chronic conditions account for a disproportionate amount of Medicare spending. If an intensive lifestyle program can reduce the risk of the most expensive disease combinations by 43%, the potential savings for the healthcare system are in the billions.

Expert Analysis and Reaction

While the study authors maintained an objective tone, the broader medical community has reacted with a mixture of validation and concern. Endocrinologists have noted that while metformin is still a valuable tool, it should not be viewed as a substitute for lifestyle changes.

"This study reinforces what we have long suspected: you cannot medicate your way out of a lifestyle problem," says one independent analysis of the data. "Metformin is excellent at what it does—lowering A1c—but it doesn’t strengthen the heart, it doesn’t clear the arteries, and it doesn’t boost the immune system the way physical activity and proper nutrition do."

Public health advocates also point out that the participants in the lifestyle group were given "booster sessions" and ongoing support. This suggests that for lifestyle changes to be effective over 20 years, they cannot be a one-time recommendation given during a 15-minute doctor’s visit. They require a sustained, community-based infrastructure.

Conclusion: A New Standard for Aging Well

The 21-year follow-up of the Diabetes Prevention Program serves as a definitive testament to the power of daily habits. Among adults at high risk for chronic disease, those who committed to a structured program of activity and nutrition were significantly more likely to age with fewer medical complications.

As the global population ages and the prevalence of metabolic disorders continues to rise, the results of this study provide a clear roadmap. While pharmacological advancements continue to offer new ways to manage specific diseases, the most effective "polypill" remains a combination of a balanced diet, regular movement, and weight management. For those with prediabetes, the message is clear: the benefits of a healthy lifestyle are not just about avoiding a single diagnosis; they are about preserving the quality of life across the entire lifespan.